CanSino biologics reports Q3 profit turnaround amid governance overhaul

CanSino Biologics Inc. reported a total profit of RMB8,487,437.46 for the nine months ended September 30, 2025, a turnaround from a loss in the prior year. This was driven by increased sales of its MCV4 vaccine, Menhycia, and a substantial rise in government grants and international funding support, totaling RMB91,601,580.37. Operating revenue increased by 22.13% to RMB692,568,069.77, while net cash flow from operating activities shifted to an inflow of RMB33,494,897.39.

Concurrently, the company announced the proposed cancellation of its board of supervisors, with its functions to be absorbed by the audit committee, along with amendments to its articles of association and other corporate governance rules. These changes aim to enhance corporate governance and standardized operations.

Furthermore, Shuifa GUI and Jianzhong LIU have tendered their resignations as independent non-executive directors due to the expiry of their six-year terms. Man CHO and Xuefeng JI have been nominated as new independent non-executive directors, pending shareholder approval, each to receive an annual director's fee of RMB300,000 (pre-tax).